Last reviewed · How we verify
Nimotuzumab Injection
Nimotuzumab is a humanized monoclonal antibody that blocks the epidermal growth factor receptor (EGFR) to inhibit tumor cell proliferation and survival.
Nimotuzumab is a humanized monoclonal antibody that blocks the epidermal growth factor receptor (EGFR) to inhibit tumor cell proliferation and survival. Used for Head and neck squamous cell carcinoma, Non-small cell lung cancer, Nasopharyngeal carcinoma.
At a glance
| Generic name | Nimotuzumab Injection |
|---|---|
| Also known as | Taixinsheng, Nimotuzumab |
| Sponsor | Biotech Pharmaceutical Co., Ltd. |
| Drug class | EGFR inhibitor monoclonal antibody |
| Target | EGFR (Epidermal Growth Factor Receptor) |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | FDA-approved |
Mechanism of action
Nimotuzumab binds to EGFR on cancer cells, preventing ligand-induced activation and downstream signaling through the PI3K/Akt and MAPK/ERK pathways. This leads to reduced cell proliferation, increased apoptosis, and enhanced radiosensitivity in EGFR-expressing tumors. Unlike some other anti-EGFR antibodies, nimotuzumab has a lower incidence of severe skin toxicity due to its lower binding affinity for EGFR.
Approved indications
- Head and neck squamous cell carcinoma
- Non-small cell lung cancer
- Nasopharyngeal carcinoma
Common side effects
- Acneiform rash
- Infusion reactions
- Hypomagnesemia
- Diarrhea
- Nausea
Key clinical trials
- Postoperative Radiotherapy Combined With Nimotuzumab Followed by Bemcentinib in High-Risk Patients With Head and Neck Squamous Cell Carcinoma (PHASE3)
- HRS-4642 in Combination With Nimotuzumab and Chemotherapy for BRPC With KRAS G12D Mutation (PHASE2)
- Nimotuzumab Combined With Toripalimab and Chemotherapy for Locally Advanced Tonsillar Cancer (PHASE2)
- Compare Radiotherapy Plus Nimotuzumab Versus Radiotherapy Alone in Platinum-ineligible Patients With Locoregionally Advanced Head and Neck Squamous Cell Carcinoma (PHASE3)
- Clinical Study of Carbon Ion Radiotherapy for Pancreatic Cancer. (NA)
- Nimotuzumab in Combined With Chemotherapy for Treatment of IVB Stage,Rrecurrent or Persistent Cervical Carcinoma (PHASE3)
- Nimotuzumab High-risk, Locally Advanced Squamous Cell Carcinoma of the Cervix (PHASE2)
- Neoadjuvant Nimotuzumab Plus Gemcitabine and Carboplatin in Unresectable Stage III Squamous Cell Lung Carcinoma (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Nimotuzumab Injection CI brief — competitive landscape report
- Nimotuzumab Injection updates RSS · CI watch RSS
- Biotech Pharmaceutical Co., Ltd. portfolio CI